Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + yohimbine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of naltrexone, an opioid receptor antagonist, and yohimbine, an alpha-2-adrenoreceptor antagonist. This combination has been studied for treating erectile dysfunction and for its effects on stress responses and anxiety. Clinical research has shown that naltrexone alters sensitivity to yohimbine, with the combination potentially causing increased anxiety, pulse, and blood pressure.
02
Targets
ADRA2B (α2B)ADRA2C (α2C)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)ADRA2A (α2A)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on naltrexone + yohimbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + yohimbine.